RA Capital β 2021 Investments
9 investments dated 2021 Β· listed companies and verified rows first Β· show all
Clinical stage oncology company developing cancer drugs paired with companion diagnostics; went public on NASDAQ (ACRV) in 2022.
Watertown, US
Board seatDerek DiRoccoΒ· per SEC Form D
BiotechSan Diego, US
Jonathan Leff(Director)Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)
Board seatPeter KolchinskyΒ· per SEC Form D
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)
BiotechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)Julie Papanek Grant(Director)Natalie Holles(Director)Daniel Becker(Director)
BoardMichael Gladstone(Director)
Board seatDerek DiRoccoΒ· per SEC Form D Β· $130M raise Β· filed Feb 2021
Philadelphia, US
Charles Roberts(Director)Gabriel Otte(Executive Officer, Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $300M raise Β· filed Dec 2021
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Mark McDade(Director)Terry Gould(Director)Adam K. Simpson(President and Chief Executive Officer)Eric Moessinger(Director)Niranjan Kanesa-thasan(Chief Medical Officer)
Board seatPeter KolchinskyΒ· per SEC Form D
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)Brian Riley(President & Chief Technical Officer)Joanne Lager(Chief Medical Officer)Wendy DiCicco(Chief Financial Officer)Adrian Chaisson(Chief of Staff)Daniel S. Lynch(Director)
Frontier Meds develops small-molecule drugs targeting previously undruggable protein targets using a proprietary approach to identify and exploit novel binding sites across the human proteome.
BiotechSouth San Francisco, US
Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Cameron Wheeler(Director)Gregory Chow(Executive Officer)Chris Varma, Ph.D.(Executive Officer, Director)
BiotechCambridge, US
Andrew Ashe(Executive Officer)Burt Adelman(Director)John Evans(Director)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardAnthony Philippakis(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.